Neovii Pharmaceuticals names its new CEO

By Catherine Sturman
Set to take over the role in January, Juergen Pohle will become Neovii Pharmaceuticals new Chief Executive Officer. He is currently the company’s Chie...

Set to take over the role in January, Juergen Pohle will become Neovii Pharmaceuticals new Chief Executive Officer. He is currently the company’s Chief Commercial Officer.

With a patient-focused mission to develop and market novel life-transforming therapies, Neovii has become a biopharmaceutical company with a global presence, and a leader in improving the outcomes in transplantation medicine and treatment options for haemato-oncological as well as immune disorders.

"Neovii has significantly expanded with increasing performance, paving the way to become a recognized player in transplantation medicine," commented current CEO Alexandre Sudarskis. He will continue to support Neovii as Executive Director and member of Neovii Pharmaceuticals Board.

Becoming Head of Marketing and Sales Consulting for Bayer Healthcare in Germany back in 2002, Pohle rose to become Head of Business Strategy & Intelligence, before moving to Novartis Pharma as Head of Business Development and Licensing, gaining further roles in Switzerland and the Czech Republic at the company.

Related stories

Speaking four languages: English, Germany, French and Italian, Pohle joined Neovii Pharmaceuticals in Switzerland in 2016, and has gained over 15 years’ experience in the pharmaceutical industry.

Most recently, he has led the business for Emerging Growth Markets and Institutional Customers such as UNICEF for Novartis Vaccines and Diagnostics AG in Basel.

Chairman David Fuhrer commented: "Juergen's leadership skills, his long-term proven track record and his many years of international experience in the pharmaceutical industry make him the ideal candidate for the position of CEO.

We are extremely pleased that Juergen has embraced the challenge of further driving the development and growth of Neovii."

Share

Featured Articles

Philip Morris International (PMI) in agreement with KT&G

PMI and KT&G are building a smoke-free world. In a new agreement between the two companies, smoke-free alternatives are within reach for smokers

Health tech leader Philips shares sustainability ambition

Roy Jakobs, Royal Philips CEO, says the health technology company’s sustainability impact plan will ‘enhance accountability & strengthen talent’

Automating gene therapy & pharma discovery at Automata

Sonia Jassi, Drug Discovery & Synthetic Biology Lead at Automata, explains how automation increases efficiency in gene therapy laboratories

Itai Hayut, CEO of Scopio Labs, on AI & blood cancer

Technology & AI

2023 predictions with Harshit Jain, global CEO of Doceree

Telehealth & COVID-19

Wolters Kluwer Health: health equity and telehealth

Telehealth & COVID-19